Switch theme
Sign up to access all valuation multiples
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
1999
316
LTM Revenue $107M
Last FY EBITDA -$101M
$168M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Agenus has a last 12-month revenue (LTM) of $107M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Agenus achieved revenue of $103M and an EBITDA of -$101M.
Agenus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Agenus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $107M | XXX | $103M | XXX | XXX | XXX |
| Gross Profit | $107M | XXX | -$52.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -51% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$101M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -98% | XXX | XXX | XXX |
| EBIT | -$66.6M | XXX | -$124M | XXX | XXX | XXX |
| EBIT Margin | -62% | XXX | -120% | XXX | XXX | XXX |
| Net Profit | -$167M | XXX | -$227M | XXX | XXX | XXX |
| Net Margin | -156% | XXX | -220% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Agenus's stock price is $3.
Agenus has current market cap of $94.0M, and EV of $168M.
See Agenus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $168M | $94.0M | XXX | XXX | XXX | XXX | $-7.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Agenus has market cap of $94.0M and EV of $168M.
Agenus's trades at 1.6x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Agenus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Agenus has a P/E ratio of -0.6x.
See valuation multiples for Agenus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94.0M | XXX | $94.0M | XXX | XXX | XXX |
| EV (current) | $168M | XXX | $168M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAgenus's last 12 month revenue growth is 2%
Agenus's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Agenus's rule of 40 is -91% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Agenus's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Agenus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -98% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -91% | XXX | -96% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agenus acquired XXX companies to date.
Last acquisition by Agenus was XXXXXXXX, XXXXX XXXXX XXXXXX . Agenus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Agenus founded? | Agenus was founded in 1999. |
| Where is Agenus headquartered? | Agenus is headquartered in United States of America. |
| How many employees does Agenus have? | As of today, Agenus has 316 employees. |
| Who is the CEO of Agenus? | Agenus's CEO is Dr. Garo H. Armen, PhD. |
| Is Agenus publicy listed? | Yes, Agenus is a public company listed on NAS. |
| What is the stock symbol of Agenus? | Agenus trades under AGEN ticker. |
| When did Agenus go public? | Agenus went public in 2000. |
| Who are competitors of Agenus? | Similar companies to Agenus include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Agenus? | Agenus's current market cap is $94.0M |
| What is the current revenue of Agenus? | Agenus's last 12 months revenue is $107M. |
| What is the current revenue growth of Agenus? | Agenus revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Agenus? | Current revenue multiple of Agenus is 1.6x. |
| Is Agenus profitable? | Yes, Agenus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
